Use Of Parpatadyarishta in the management of Prostate growth related urinary incontinence

Randomized Controlled clinical trial of Parpatadyarishta in the management of Vatashthila with special reference to Benign Prostatic Hyperplasia.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/019230

Enrollment

Registered

2019-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: PARPATADYARISHTA: Parpatadyarishta 20ml TWCE A DAY WTH EQUAL PORTON OF WATER FOR 60 DAYS Control Intervention1: Tamsulosin HCL 0.4mg: CAPSULE Tamsulosin HCL 0.4mg ONCE A DAY AT BEDTIME

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of age between 40 years to 70 years who are diagnosed case of benign Prostatic Hyperplasia. 2.Patients having International Prostate Symptom Score (IPSS) [9] of mild to moderate score (IPSS 3.Patients having post voiding residue of more than 200 ml.[9] 4.Patient Having PSA lower than 4.0 ng/mL[9] 5.Prostate Weight less than 60 gm. 6.Patients and/or his signatory guardian/responsible person had understood the Consent in his own language and willing to follow the suggestion through the assessment period. (i.e. follow up intervals, medicine dose and suggested investigation and examination

Exclusion criteria

Exclusion criteria: 1.Diagnosed case of bladder & prostate cancer. 2.Any prior surgery which could induce dysuria. 3.Patients having urinary flow less than 5ml/sec. 4.Patient having acute urinary tract infection 5.Urethral Stricture.

Design outcomes

Primary

Measure	Time frame
relief in Bladder outlet Obstruction by relief in 1.Incomplete emptying of Bladder 2.Increased Frequency of Urine 3.Intermittency in urination 4.Urgency in micturition 5.Weak Stream of urine 6.Straining during Urinaton 7.Nocturia Timepoint: 1.International Prostate Symptom Score (IPSS) on Day one, 15TH DAY, 30TH DAY, 45TH DAY, 60TH DAY 2.International Prostate Symptom Score Quality Of Life Index I.P.S.S. QOL on Day one, 15TH DAY, 30TH DAY, 45TH DAY, 60TH DAY 3.Digital Rectal Examination DRE on Day one, 15TH DAY, 30TH DAY, 45TH DAY, 60TH DAY 4.Urine Flow (Uroflowmetry) Day one and 60TH DAY 5.Post Void Residual Urine Volume Ultrasnography on Day one and 60TH DAY	—

Measure

Time frame

relief in Bladder outlet Obstruction by relief in 1.Incomplete emptying of Bladder 2.Increased Frequency of Urine 3.Intermittency in urination 4.Urgency in micturition 5.Weak Stream of urine 6.Straining during Urinaton 7.Nocturia Timepoint: 1.International Prostate Symptom Score (IPSS) on Day one, 15TH DAY, 30TH DAY, 45TH DAY, 60TH DAY 2.International Prostate Symptom Score Quality Of Life Index I.P.S.S. QOL on Day one, 15TH DAY, 30TH DAY, 45TH DAY, 60TH DAY 3.Digital Rectal Examination DRE on Day one, 15TH DAY, 30TH DAY, 45TH DAY, 60TH DAY 4.Urine Flow (Uroflowmetry) Day one and 60TH DAY 5.Post Void Residual Urine Volume Ultrasnography on Day one and 60TH DAY

—

Secondary

Measure	Time frame
Parpatadyarishta by reducing Prostate Size or retarding further growthTimepoint: Prostate Size By Ultrasnography on Day one and 60TH DAY of treatment	—

Countries

India

Contacts

Public ContactDR GANESH SHANKARRAO JOJARE

CSMSS AYURVED MAHAVIDYALAYA

drshubhada26@gmail.com9860022209

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026